Log in
Enquire now
‌

US Patent 10925885 Thyromimetics for the treatment of fatty liver diseases

Patent 10925885 was granted and assigned to METABASIS THERAPEUTICS, INC. on February, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
‌
METABASIS THERAPEUTICS, INC.
Current Assignee
‌
METABASIS THERAPEUTICS, INC.
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10925885
Date of Patent
February 23, 2021
Patent Application Number
16195782
Date Filed
November 19, 2018
Patent Citations
‌
US Patent 10130643 Thyromimetics for the treatment of fatty liver diseases
Patent Citations Received
‌
US Patent 12102646 Compositions for the treatment of fibrosis and inflammation
0
‌
US Patent 11707472 Compositions for the treatment of fibrosis
0
‌
US Patent 11787828 Crystalline forms and methods of producing crystalline forms of a compound
Patent Primary Examiner
‌
Sudhakar Katakam
Patent abstract

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10925885 Thyromimetics for the treatment of fatty liver diseases

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us